Open AccessP1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST‐EFFECTIVENESS ANALYSIS
Author(s) -
Kanevsky D.,
Elgart J.,
Zerga M.,
Glancszpigel M.,
Morisset P.
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000849708.27871.d6
Subject(s) - obinutuzumab , venetoclax , medicine , bendamustine , chronic lymphocytic leukemia , ibrutinib , cost effectiveness , chlorambucil , oncology , leukemia , chemotherapy , risk analysis (engineering) , cyclophosphamide